Generic Dextenza Availability
Last updated on Mar 13, 2025.
Dextenza is a brand name of dexamethasone ophthalmic, approved by the FDA in the following formulation(s):
DEXTENZA (dexamethasone - insert;ophthalmic)
-
Manufacturer: OCULAR THERAPEUTIX
Approval date: November 30, 2018
Strength(s): 0.4MG [RLD]
Is there a generic version of Dextenza available?
No. There is currently no therapeutically equivalent version of Dextenza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dextenza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Punctal plug and bioadhesives
Patent 11,458,041
Issued: October 4, 2022
Inventor(s): Silverberg; Noah et al.
Assignee(s): Ocular Therapeutix, Inc. (Bedford, MA)The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dryeye using a bioadhesive without use of a punctal plug.
Patent expiration dates:
- November 16, 2037✓
- November 16, 2037✓
- November 16, 2037
-
Methods of treating allergic conjunctivitis
Patent 12,144,889
Issued: November 19, 2024
Inventor(s): Goldstein; Michael
Assignee(s): OCULAR THERAPEUTIX, INC. (Bedford, MA)Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis.
Patent expiration dates:
- April 26, 2041✓
- April 26, 2041
-
Punctal plug and bioadhesives
Patent 12,150,896
Issued: November 26, 2024
Inventor(s): Silverberg; Noah et al.
Assignee(s): OCULAR THERAPEUTIX, INC. (Bedford, MA)The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.
Patent expiration dates:
- October 7, 2036✓
- October 7, 2036✓
- October 7, 2036
-
Drug delivery through hydrogel plugs
Patent 8,409,606
Issued: April 2, 2013
Inventor(s): Sawhney Amarpreet S. & Jarrett Peter & Bassett Michael & Blizzard Charles
Assignee(s): Incept, LLCAn embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.
Patent expiration dates:
- May 14, 2030✓
- May 14, 2030
-
Drug delivery through hydrogel plugs
Patent 8,563,027
Issued: October 22, 2013
Inventor(s): Jarrett Peter & Bassett Michael & Blizzard Charles D. & Sawhney Amarpreet S.
Assignee(s): Incept, LLCAn embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.
Patent expiration dates:
- February 12, 2030✓
- February 12, 2030
More about Dextenza (dexamethasone ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic steroids
- Breastfeeding
- En español
Patient resources
Other brands
Ozurdex, Maxidex, Dexycu, Ocu-Dex
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.